SGRY

Analyst Note: Surgery Partners, Inc. (SGRY)

Date: 2026-06-20 Current Price: $14.55

1. Structural Readiness

• Aggressive/Pre-Breakout Entry: Not recommended as a standalone signal; requires confirmation of the breakout to be actionable.
• Breakout Level: Not yet fired.
• Current Price: $14.55.
• Extension: Not applicable (price has not yet extended from a breakout).
• ATR Context: Current ATR is 3.7% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 3.7% is acceptable for sizing), indicating manageable volatility for position sizing without the elevated risk of >6% ATR.

2. Thesis Layer

As of 2026-06-20, SGRY is a TACTICAL, setup-led name. There is NO named secular thesis attached to this specific setup in the current context. The conviction must be derived strictly from the quality of the technical setup (the forming coil) and the underlying business fundamentals (revenue growth, margin inflection, and capital deployment) rather than a macro secular trend. The analysis must judge the name on its structural readiness and operational execution, not on invented thematic narratives.

3. Business Overview

Company & Model: Surgery Partners, Inc. operates a portfolio of surgical facilities, primarily Ambulatory Surgical Centers (ASCs) and surgical hospitals, in partnership with physicians. The company focuses on multi-specialty facilities where physicians perform non-emergency surgical procedures.

• Portfolio: As of March 31, 2026, the company owned or operated 180 surgical facilities (161 ASCs and 19 surgical hospitals) across 30 states.
• Specialties: Key focus areas include orthopedics (musculoskeletal), ophthalmology, gastroenterology (GI), and general surgery.
• Strategy: The company is actively expanding its "higher acuity" capabilities, evidenced by the deployment of 73 surgical robots across the platform and the opening of 9 de novo ASCs over the trailing 12 months (1 in Q1 2026).

Financial Performance (Q1 2026 & Full Year Guidance):

• Revenue: Q1 2026 revenue increased 4.5% year-over-year to $810.9 million (from $776.0 million in Q1 2025).
• Same-Facility Trends: Days-adjusted same-facility revenues grew 4.4%, driven by a 3.8% increase in revenue per case and a 0.6% increase in same-facility cases.
• EBITDA: Q1 2026 Adjusted EBITDA decreased 1.5% to $102.3 million (from $103.9 million in Q1 2025).
• Guidance (Reiterated May 5, 2026):
• Full Year 2026 Revenue: $3.35 billion to $3.45 billion.
• Full Year 2026 Adjusted EBITDA: At least $530 million.
• Q2 Expectations: Revenue expected to represent 24% to 24.5% of the annual target; EBITDA expected to represent 23% to 23.5%.

Capital Deployment & M&A:

• Capex: Q1 2026 capital deployment was approximately $4 million. Management targets $200 million in annual capital deployment.
• M&A Activity: The company acquired a controlling interest in one surgical facility for $4.2 million in Q1 2026.
• Pipeline: Management is in advanced discussions on a "key opportunity" in a larger surgical hospital market, targeting an announcement in mid-2026.

4. Archetype and Conviction

Archetype: Margin Inflector.

• Rationale: The company is demonstrating a classic margin inflector profile through operational leverage and strategic capital allocation. While Q1 EBITDA dipped slightly (-1.5%) against revenue growth (+4.5%), the guidance for the full year targets an EBITDA margin expansion (implied by the $530M+ target against $3.35B-$3.45B revenue). The company is actively deploying capital ($200M target) to acquire and build facilities that are expected to accrete earnings. The recruitment of 140 physicians (concentrated in high-value specialties like orthopedics and ophthalmology) and the addition of 73 surgical robots suggest a strategic shift toward higher-acuity, higher-margin procedures.

Conviction Stack:

• Thesis Strength: Moderate. Lacks a named macro thesis, relying on tactical execution.
• Evidence Quality: High. Strong, specific guidance and operational metrics from Q1 2026 and the May 5 earnings call.
• Rerating Potential: Dependent on the successful execution of the mid-2026 M&A announcement and the realization of the $200M annual capex target.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• M&A Announcement: The successful closing of the "key opportunity" in a larger surgical hospital market as targeted for mid-2026.
• Margin Expansion: Q2 or H1 2026 results showing EBITDA growth outpacing revenue growth, confirming the margin inflector thesis.

What Would Invalidate the Case:

• Guidance Miss: A significant miss on the full-year revenue or EBITDA guidance, or a downgrade in guidance.
• M&A Failure: Failure to announce the key opportunity by mid-2026 or a failure to close the deal.

Gaps in Evidence:

• Valuation Multiples: No current P/E, EV/EBITDA, or P/S multiples are provided in the evidence block to contextualize the $14.55 price against historical or peer valuations.
• Debt Structure: No specific details on leverage ratios or debt maturity schedules are provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue growth of 4.5% to $810.9M; Reiterated full-year EBITDA guidance of at least $530M; Active pipeline with 140 physician recruits and 73 surgical robots deployed. Key risks: Q1 EBITDA declined 1.5% despite revenue growth; Forming coil has not yet fired a breakout; M&A announcement timing is contingent on "mid-2026" execution. Sizing hint: Position size should be conservative given the "forming" state and lack of confirmed breakout; utilize the 3.7% ATR for volatility-based sizing. Expected path: Management targets a mid-2026 M&A announcement and $200M annual capex deployment; if the breakout fires, the setup transitions to active confirmation. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).